AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results